Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, mainly due to late diagnosis at advanced tumor stages. In this study, we aimed to identify plasma protein biomarkers for early detection of PDAC. Totally, 135 PDAC patients (early PDAC, Stage I/II, n = 71; advanced PDAC, Stage III/IV, n =...

Descripción completa

Detalles Bibliográficos
Autores: Yu, Jingru, Ploner, Alexander, Kordes, Maximilian, Löhr, J. Matthias, Nilsson, Magnus, López De Maturana, Evangelina, Estudillo, Lidia, Renz, Harald, Carrato, Alfredo, Molero, Xavier, Real, Francisco X., Malats i Riera, Núria, Ye, Weimin
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/46533
Acceso en línea:http://hdl.handle.net/10230/46533
http://dx.doi.org/10.1002/ijc.33464
Access Level:acceso abierto
Palabra clave:AUC
Biomarkers
Early diagnosis
Pancreatic ductal adenocarcinoma
Proteomics
id ES_4b8916c5649d4e7fdff93fe5a492b218
oai_identifier_str oai:recercat.cat:10230/46533
network_acronym_str ES
network_name_str España
repository_id_str
spelling Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinomaYu, JingruPloner, AlexanderKordes, MaximilianLöhr, J. MatthiasNilsson, MagnusLópez De Maturana, EvangelinaEstudillo, LidiaRenz, HaraldCarrato, AlfredoMolero, XavierReal, Francisco X.Malats i Riera, NúriaYe, WeiminAUCBiomarkersEarly diagnosisPancreatic ductal adenocarcinomaProteomicsPancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, mainly due to late diagnosis at advanced tumor stages. In this study, we aimed to identify plasma protein biomarkers for early detection of PDAC. Totally, 135 PDAC patients (early PDAC, Stage I/II, n = 71; advanced PDAC, Stage III/IV, n = 64), 13 benign lesions/chronic pancreatitis patients and 72 healthy individuals, with corresponding plasma samples from a case-control study in Sweden were included. A proximity extension assay was used to detect 92 cancer-related proteins, and an enzyme-linked immunosorbent assay/electrochemiluminescence immunoassay was used to detect CA19-9. Predictive features were selected from these 93 candidate proteins and three covariates in the Swedish participants, and then validated in Spanish participants, including 37 early PDAC patients, 38 advanced PDAC patients, 19 chronic pancreatitis patients and 36 healthy controls. A panel of eight proteins discriminating early PDAC from healthy individuals was identified, and the cross-validated area under the curves (AUCs) were 0.85 (95% confidence interval, 95% CI, 0.78-0.91) and 0.81 (95% CI, 0.70-0.92) in the Swedish and Spanish participants, respectively. Another eight-protein panel was predictive for classifying advanced PDAC from healthy controls in two populations, with cross-validated AUCs of 0.89 (95% CI, 0.83-0.95) and 0.90 (95% CI, 0.83-0.98), respectively. In conclusion, eight protein biomarkers were identified and externally validated, potentially allowing early detection of PDAC patients if validated in additional prospective studies.Wiley202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/46533http://dx.doi.org/10.1002/ijc.33464reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésInt J Cancer. 2021; 148(8):2048-58© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/465332026-05-29T05:05:01Z
dc.title.none.fl_str_mv Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
title Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
spellingShingle Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
Yu, Jingru
AUC
Biomarkers
Early diagnosis
Pancreatic ductal adenocarcinoma
Proteomics
title_short Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
title_full Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
title_fullStr Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
title_full_unstemmed Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
title_sort Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
dc.creator.none.fl_str_mv Yu, Jingru
Ploner, Alexander
Kordes, Maximilian
Löhr, J. Matthias
Nilsson, Magnus
López De Maturana, Evangelina
Estudillo, Lidia
Renz, Harald
Carrato, Alfredo
Molero, Xavier
Real, Francisco X.
Malats i Riera, Núria
Ye, Weimin
author Yu, Jingru
author_facet Yu, Jingru
Ploner, Alexander
Kordes, Maximilian
Löhr, J. Matthias
Nilsson, Magnus
López De Maturana, Evangelina
Estudillo, Lidia
Renz, Harald
Carrato, Alfredo
Molero, Xavier
Real, Francisco X.
Malats i Riera, Núria
Ye, Weimin
author_role author
author2 Ploner, Alexander
Kordes, Maximilian
Löhr, J. Matthias
Nilsson, Magnus
López De Maturana, Evangelina
Estudillo, Lidia
Renz, Harald
Carrato, Alfredo
Molero, Xavier
Real, Francisco X.
Malats i Riera, Núria
Ye, Weimin
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv AUC
Biomarkers
Early diagnosis
Pancreatic ductal adenocarcinoma
Proteomics
topic AUC
Biomarkers
Early diagnosis
Pancreatic ductal adenocarcinoma
Proteomics
description Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, mainly due to late diagnosis at advanced tumor stages. In this study, we aimed to identify plasma protein biomarkers for early detection of PDAC. Totally, 135 PDAC patients (early PDAC, Stage I/II, n = 71; advanced PDAC, Stage III/IV, n = 64), 13 benign lesions/chronic pancreatitis patients and 72 healthy individuals, with corresponding plasma samples from a case-control study in Sweden were included. A proximity extension assay was used to detect 92 cancer-related proteins, and an enzyme-linked immunosorbent assay/electrochemiluminescence immunoassay was used to detect CA19-9. Predictive features were selected from these 93 candidate proteins and three covariates in the Swedish participants, and then validated in Spanish participants, including 37 early PDAC patients, 38 advanced PDAC patients, 19 chronic pancreatitis patients and 36 healthy controls. A panel of eight proteins discriminating early PDAC from healthy individuals was identified, and the cross-validated area under the curves (AUCs) were 0.85 (95% confidence interval, 95% CI, 0.78-0.91) and 0.81 (95% CI, 0.70-0.92) in the Swedish and Spanish participants, respectively. Another eight-protein panel was predictive for classifying advanced PDAC from healthy controls in two populations, with cross-validated AUCs of 0.89 (95% CI, 0.83-0.95) and 0.90 (95% CI, 0.83-0.98), respectively. In conclusion, eight protein biomarkers were identified and externally validated, potentially allowing early detection of PDAC patients if validated in additional prospective studies.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/46533
http://dx.doi.org/10.1002/ijc.33464
url http://hdl.handle.net/10230/46533
http://dx.doi.org/10.1002/ijc.33464
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Int J Cancer. 2021; 148(8):2048-58
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407566682914816
score 15.81155